黄芩苷在呼吸系统疾病中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.13.005

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (13): 1794-1797.DOI: 10.3760/cma.j.issn.1007-1245.2023.13.005

黄芩苷在呼吸系统疾病中的研究进展

邝哲姝吴福玲

滨州医学院附属医院儿科，滨州　256600

收稿日期:2022-09-16 出版日期:2023-07-01 发布日期:2023-07-21
通讯作者: 吴福玲，Email：wufuling000@163.com
基金资助:
山东省自然科学基金（ZR2014HL001）；山东省医药卫生科技发展计划项目（2013WS0312）；滨州市软科学研究计划项目（2016BRK19）

Research progress of baicalin in respiratory diseases

Kuang Zheshu, Wu Fuling

Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256600, China

Received:2022-09-16 Online:2023-07-01 Published:2023-07-21
Contact: Wu Fuling, Email: wufuling000@163.com
Supported by:
Natural Science Foundation of Shandong Province (ZR2014HL001); Medical Health Science and Technology Development Plan Project of Shandong Province (2013WS0312); Binzhou Soft Science Research Project (2016BRK19)

摘要/Abstract

摘要：

中药黄芩苷的药理活性具有抗氧化、抗炎、抗癌和抗病毒等作用，其主要功效可用于支气管炎、哮喘、支原体肺炎等呼吸系统疾病的治疗。近年来，越来越多的研究发现，黄芩苷治疗各种肺部疾病的机制各不相同，本文就最新发现的黄芩苷在呼吸系统疾病中的研究进展做一综述。

关键词:

呼吸系统疾病, 黄芩苷, 分子通路, 进展

Abstract:

The pharmacological activity of traditional Chinese medicine baicalin has anti-oxidation, anti-inflammatory, anticancer, and antiviral effects, and its main effects can be used in the treatment of bronchitis, asthma, mycoplasma pneumonia, and other respiratory diseases. In recent years, more and more studies have found that the mechanism of baicalin in treating various lung diseases is different. This paper aims to review the research progress of the latest discovery of baicalin in respiratory diseases.

Key words:

Respiratory diseases, Baicalin, Molecular pathway, Progress

邝哲姝吴福玲.

黄芩苷在呼吸系统疾病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(13): 1794-1797.

Kuang Zheshu, Wu Fuling.

Research progress of baicalin in respiratory diseases [J]. International Medicine and Health Guidance News, 2023, 29(13): 1794-1797.

参考文献

[1] 朱丹妮, 高山林, 陈柏君. 黄岑同源四倍体株系中黄岑苷含量的比较 [J]. 药物生物技术, 2001, (6): 313-316. DOI:10.19526/j.cnki.1005-8915.2001.06.004.
[2] Wu H, Long X, Yuan F, et al. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin [J]. Acta Pharm Sin B, 2014, 4(3): 217-226. DOI: 10.1016/j.apsb.2014.03.002.
[3] Chang H, Meng HY, Bai WF, et al. A metabolomic approach to elucidate the inhibitory effects of baicalin in pulmonary fibrosis[J]. Pharm Bio, 2021,59(1): 1016-1025. DOI: 10.1080/13880209.2021.1950192.
[4] Hao D, Li Y, Shi J, et al. Baicalin alleviates chronic obstructive pulmonary disease through regulation of HSP72-mediated JNK pathway [J]. Mol Med, 2021, 27(1): 53. DOI: 10.1186/s10020-021-00309-z.
[5] Zhang H, Liu B, Jiang S, et al. Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF-kappaB/PAI-1 signalling [J]. Pulm Pharmacol Ther, 2021, 70: 102061. DOI: 10.1016/j.pupt.2021.102061.
[6] Arndt PG, Suzuki N, Avdi NJ, et al. Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways [J]. J Biol Chem, 2004, 279(12): 10883-10891. DOI: 10.1074/jbc.M309901200.
[7] Maneechotesuwan K. Role of microRNA in severe asthma [J]. Respir Investig, 2019, 57(1): 9-19. DOI: 10.1016/j.resinv.2018.10.005.
[8] Zhai C, Wang D. Baicalin regulates the development of pediatric asthma via upregulating microRNA-103 and mediating the TLR4/NF-kappaB pathway [J]. J Recept Signal Transduct Res, 2021: 1-11. DOI:10.1080/10799893.2021.1900865
[9] Yoshida K, Takabayashi T, Kaneko A, et al. Baicalin suppresses type 2 immunity through breaking off the interplay between mast cell and airway epithelial cell [J]. J Ethnopharmacol, 2021, 267: 113492. DOI: 10.1016/j.jep.2020.113492.
[10] Yang M, Meng F, Wang K, et al. Interleukin 17A as a good predictor of the severity of Mycoplasma pneumoniae pneumonia in children [J]. Sci Rep, 2017, 7(1): 12934. DOI: 10.1038/s41598-017-13292-5.
[11] Zhang H, Li X, Wang J, et al. Baicalin relieves Mycoplasma pneumoniae infectioninduced lung injury through regulating microRNA221 to inhibit the TLR4/NFkappaB signaling pathway [J]. Mol Med Rep, 2021, 24(2): 571. DOI: 10.3892/mmr.2021.12210.
[12] Kolsuz M, Erginel S, Alataş O, et al. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia [J]. Respiration, 2003, 70(6): 615-622. DOI: 10.1159/000075208.
[13] Fu Y, Shen J, Li Y, et al. Inhibition of the PERK/TXNIP/NLRP3 Axis by Baicalin Reduces NLRP3 Inflammasome-Mediated Pyroptosis in Macrophages Infected with Mycobacterium tuberculosis [J]. Mediators Inflamm, 2021, 2021: 1805147. DOI: 10.1155/2021/1805147.
[14] Hu Y, Jiang L, Lai W, et al. MicroRNA-33a disturbs influenza A virus replication by targeting ARCN1 and inhibiting viral ribonucleoprotein activity [J]. J Gen Virol, 2016, 97(1): 27-38. DOI: 10.1099/jgv.0.000311.
[15] Li R, Wang L. Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR146a [J]. Mol Med Rep, 2019, 20(6): 5041-5049. DOI: 10.3892/mmr.2019.10743.
[16] Huang YF, Bai C, He F, et al. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19) [J]. Pharmacol Res, 2020, 158: 104939. DOI: 10.1016/j.phrs.2020.104939.
[17] Zandi K, Musall K, Oo A, et al. Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase [J]. Microorganisms, 2021, 9(5): 893. DOI: 10.3390/microorganisms9050893.
[18] Gour A, Manhas D, Bag S, et al. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2 [J]. Phytother Res, 2021, 35(8): 4258-4283. DOI: 10.1002/ptr.7092.
[19] Liu H, Ye F, Sun Q, et al. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro [J]. J Enzyme Inhib Med Chem, 2021, 36(1): 497-503. DOI: 10.1080/14756366.2021.1873977.
[20] 徐明杭, 蒙艳丽, 王晓溪, 等. 黄芩苷对肺纤维化小鼠组织中纤维化因子TGF-β1及mmp2,timp2表达的影响 [J]. 中国中药杂志, 2020, 45(23): 5738-5744. DOI: 10.19540/j.cnki.cjcmm.20200908.401
[21] Zhao H, Li C, Li L, et al. Baicalin alleviates bleomycininduced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway [J]. Mol Med Rep, 2020, 21(6): 2321-2334. DOI: 10.3892/mmr.2020.11046.
[22] Huang TT, Lan YW, Chen CM, et al. Antrodia cinnamomea induces anti-tumor activity by inhibiting the STAT3 signaling pathway in lung cancer cells [J]. Sci Rep, 2019, 9(1): 5145. DOI: 10.1038/s41598-019-41653-9.
[23] Diao X, Yang D, Chen Y, et al. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase [J]. Biosci Rep, 2019, 39(4): BSR20181692. DOI: 10.1042/BSR20181692.
[24] Zhao F, Zhao Z, Han Y, et al. Baicalin suppresses lung cancer growth phenotypes via miR-340-5p/NET1 axis [J]. Bioengineered, 2021, 12(1): 1699-1707. DOI: 10.1080/21655979.2021.1922052.
[25] Sui X, Han X, Chen P, et al. Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/mTOR Signaling Pathway [J]. Front Mol Biosci, 2020, 7: 602282. DOI: 10.3389/fmolb.2020.602282.
[26] Hou Y, Pi C, Feng X, et al. Antitumor Activity In Vivo and Vitro of New Chiral Derivatives of Baicalin and Induced Apoptosis via the PI3K/Akt Signaling Pathway [J]. Mol Ther Oncolytics, 2020, 19: 67-78. DOI: 10.1016/j.omto. 2020.08.018.
[27] Yin Z, Chen E, Cai X, et al. Baicalin attenuates XRCC1-mediated DNA repair to enhance the sensitivity of lung cancer cells to cisplatin [J]. J Recept Signal Transduct Res, 2021, 42(3): 215-224. DOI: 10.1080/10799893.2021. 1892132.

黄芩苷在呼吸系统疾病中的研究进展

Research progress of baicalin in respiratory diseases

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

[1]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[2]	周鸿明李云逸李伟龙宋卓恒陈宇曹锐胡波栾韶东尹良红. 机器学习在血液透析治疗中的应用进展 [J]. 国际医药卫生导报, 2023, 29(13): 1777-1781.
[3]	周建国符大勇王蕴丹. 无创性影像技术在缺血性脑卒中血脑屏障通透性评估方面的应用进展 [J]. 国际医药卫生导报, 2023, 29(13): 1786-1789.